Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

Yalcin, SuayibDane, FaysalOksuzoglu, BernaYildirim, NuriyeIsikdogan, AbdurrahmanOzkan, MetinDemirag, Guzin2024-04-242024-04-2420180732-183X1527-7755https://doi.org/10.1200/JCO.2018.36.4_suppl.346https://hdl.handle.net/11468/18302Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO) -- JAN 18-20, 2018 -- San Francisco, CA[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.Conference Object364WOS:00043617410033110.1200/JCO.2018.36.4_suppl.346Q1